90Yttrium-labelled Anti-CD66 Monoclonal Antibody as Part of a Reduced Toxicity Conditioning Regimen Prior to Allogeneic Haematopoietic Stem Cell Transplantation: an Open Label, Phase II Study in Children and Adolescents With High Risk Leukaemia
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Besilesomab Y 90 (Primary)
- Indications Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms RITII
- 29 Sep 2023 Planned End Date changed from 1 Jun 2024 to 30 Sep 2025.
- 29 Sep 2023 Planned primary completion date changed from 1 Oct 2023 to 30 Sep 2025.
- 29 Sep 2023 Status changed from not yet recruiting to recruiting.